GSTCD

Across TCGA pan-cancer cohorts, GSTCD mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GSTCD data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GSTCD mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GSTCD expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

PDAC, UCEC, and CCRCC are the cancer types where GSTCD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.259	0.551	.002	34	view →
UCEC	DFS	Median	III,IV	1.000	0.488	.013	8	view →
CCRCC	DFS	Tertile	III,IV	0.447	0.789	.028	6	view →
LUAD	OS	Quartile	All	0.690	0.922	.013	3	view →
GBM	OS	Median	All	0.620	0.435	.032	2	view →
LSCC	DFS	Median	All	0.796	0.626	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GSTCD–PDAC (OS)

Open the PDAC breakdown →